Can calcitonin nasal spray reduce the risk of recurrence of central giant cell granuloma of the jaws? A double-blind clinical trial.

Recurrence is a major problem following the treatment of aggressive central giant cell granuloma (CGCG). The aim of this study was to compare the frequency of recurrence between patients who received calcitonin nasal spray after curettage of CGCGs and those who did not. A double-blind clinical trial was designed. Patients were allocated to one of two groups: those in the calcitonin group underwent curettage and received calcitonin salmon nasal spray 200IU/day once a day for 3 months after surgery; those in the control group underwent curettage of CGCGs and received a placebo once a day for 3 months after surgery. All patients were followed for 5 years after surgery. Twenty-four patients were treated in the two groups. There was no difference in age, sex, tumour size, or tumour location between the two groups (P>0.05). Eight of the 24 patients (33.3%) had recurrences during the follow-up period: one in the calcitonin group (9.1%) and seven in the control group (53.8%). Analysis of the data demonstrated a significant difference between the two study groups (P=0.033). It appears that calcitonin nasal spray may reduce the frequency of recurrence in aggressive CGCGs in the mandible and maxilla.

[The clinical and therapeutic aspects of epulis gravidarum]. / Aspetti clinici e terapeutici dell'epulide gravidica.

Preventive oral hygiene performed with particular care is the only possible means of preventing the occurrence and the recurrence of phlogistic phenomena of the stomatologic apparatus of pregnant women. However in the case of epulis surgical treatment of the lesion completes preventive care, followed by a plan of postpartum hygiene to eliminate local causes and to prevent recurrences together with therapy for the elimination of periodontal pockets and infrabony pockets, to a restitution ad integrum of the general conditions of the oral cavity.